AstraZeneca Deepens Gene Editing Capabilities with Revvity Partnership
BIOMARKER
1. AstraZeneca has entered a non-exclusive licensing agreement with Revvity to enhance its gene editing capabilities.
2. The partnership aims to develop cell therapies for cancer and immune-mediated conditions using Revvity's Pin-point base editing platform.
3. Pin-point utilizes a modified Cas enzyme to enable precise and efficient gene edits while minimizing off-target effects.
4. The agreement will support Revvity's goal of advancing its base editing platform into clinical applications.
5. Unlike traditional CRISPR-based technologies, Pin-point cuts only one strand of DNA to correct faulty bases.
6. Pin-point is a modular technology that can be tailored for optimal therapeutic performance based on the target gene.
7. The platform has demonstrated potential in various cell types and therapeutic indications, including induced pluripotent stem cells and T-cells.
8. AstraZeneca's gene editing toolbox already includes CRISPR GUARD and CRISPR VIVO, and Pin-point will be a valuable addition.
9. AstraZeneca collaborates with academic institutions and industry partners to expand its gene and cell therapy portfolios.
10. The partnership with Revvity follows AstraZeneca's recent acquisitions of Neogene Therapeutics and LogicBio Therapeutics to strengthen its capabilities in T-cell therapies and gene editing.